The field of electrophysiology is a rapidly growing market right now. As new technologies and innovations are being developed, new and exciting opportunities emerge. Autonomix is positioned to be a major player in this field with its precision-guided sense, treat and verify technology that sits at the core of an estimated 100 billion dollar market opportunity.

Given the significant unmet need, proving the effectiveness of Autonomix’s technology in pancreatic cancer provides the most direct and cost-effective path towards a potential approval. The progress Autonomix has generated to date in pancreatic cancer pain, pain that originates from the Celiac Plexus nerve, underscores the potential of its technology to significantly benefit patients suffering from pain.

Once the effectiveness of the Autonomix technology is demonstrated, reach can be expanded into additional high-value indications that drive shareholder value. This includes additional visceral cancer pain, tumor-pain and abdominal pain indications, future potential uses in treating hypertension, addressing other sources of pain including lower back and other joint locations, and more. The opportunity landscape exists wherever the nervous system is involved, including urinary tract disorders, pulmonary diseases, digestive issues and a myriad of other organ-related disorders.

The Full Autonomix Market Opportunity